Abstract

* Lixisenatide (Adlyxin), a glucagon-like peptide-1 (GLP-1) receptor agonist, has been approved by the Food and Drug Administration to treat type 2 diabetes. It's administered once daily by subcutaneous injection. * The drug's most common adverse effects are gastrointestinal distress, headache, and dizziness. * GLP-1 receptor agonists are playing an increasingly important role in the management of type 2 diabetes, and nurses should be aware of the various available drugs in this class.